Jim Simons’s Structure Therapeutics GPCR Stock Holding History

Jim Simons’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,800	Closed	-$2.69M	–	3359
2026 Q1	$2.69M	Sell	55,800 -59,400	-52%	-$4.07M	﹤0.01%	1718
2025 Q4	$8.01M	Sell	115,200 -38,700	-25%	-$1.58M	0.01%	1035
2025 Q3	$4.31M	Buy	153,900 +42,000	+38%	+$837K	0.01%	1587
2025 Q2	$2.32M	Buy	111,900 +96,100	+608%	+$2.11M	﹤0.01%	2023
2025 Q1	$273K	Buy	+15,800	New	+$387K	﹤0.01%	2960
2024 Q3	–	Sell	-35,700	Closed	-$1.4M	–	3663
2024 Q2	$1.4M	Buy	+35,700	New	+$1.47M	﹤0.01%	2112
2023 Q3	–	Sell	-32,900	Closed	-$1.37M	–	3830
2023 Q2	$1.37M	Buy	+32,900	New	+$922K	﹤0.01%	2250

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jim Simons's GPCR Position: Q2 2026 in Review

Jim Simons sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 55,800 shares — an estimated $2.69M sold.

Jim Simons first reported a position in GPCR in Q2 2023 and held it in 7 quarters. The position peaked at $8.01M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Jim Simons reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
Jim Simons sold 55,800 Structure Therapeutics shares in Q2 2026, an estimated $2.69M.
Jim Simons first reported a position in Structure Therapeutics in Q2 2023 and held it in 7 quarters.
Jim Simons's Structure Therapeutics position peaked at $8.01M in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.